Aligos Therapeutics, Inc. (ALGS)
D
Pipeline Grade
Financial Position (from SEC Filings)
$30.2M
Cash & Equivalents
$23.1M
Quarterly Burn Rate
4 mo
Est. Cash Runway
$41M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-03-01 | Phase2 Readout | — |
Active Clinical Trials (4)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06963710 | A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-... | PHASE2 | Recruiting | 200 |
| NCT06672900 | A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential ... | PHASE1 | Active Not Recruiting | 24 |
| NCT07342868 | Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Sub... | PHASE1 | Recruiting | 16 |
| NCT07342881 | Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Part... | PHASE1 | Recruiting | 30 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.